GenSight Biologics Appoints Magali Taiel as Chief Medical Officer

GenSight Biologics to present new GS010 data at the 2019 Annual Meeting of the American Academy of Ophthalmology

GenSight Biologics integrates the Enternext® PEA-PME 150 index by Euronext

GenSight Biologics reports sustained efficacy and safety at 96 weeks in RESCUE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Reports Interim Financial Results for the First Half of 2019 and Provides Operational Update

GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule

GenSight Biologics expands its Board of Directors with the appointments of Maritza McIntyre and Sofinnova Partners

GenSight Biologics announces presentation of results from the REVERSE Phase III trial of GS010 at the 14th meeting of the European Neuro-Ophthalmology Society (EUNOS)

Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude

GenSight Biologics to Host KOL Breakfast on May 23, 2019 in New York